Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease

点击翻译按钮获取中文摘要

Vivreon Biosciences, LLC 4940 Carroll Canyon Rd. Suite 110 San Diego, CA 92121 milton@vivreonbiosciences.com Vivreon Biosciences – NIA SBIR #PA-20-272 – Administrative Supplements to Existing NIH Grants and Cooperative Agreements; Notice of Special Interest (NOSI): Administrative Supplement for Providing Technical and Business Assistance (TABA) Funding to SBIR/STTR Awardees (Admin Supp) Notice Number: NOT-OD-21- 062 Project Summary Vivreon Biosciences is pleased to apply for NIA SBIR Supplement #PA-20-272 to develop intellectual property protection for the preclinical candidate in our currently funded SBIR R44AG061995, “Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease”. Supplemental funding is urgently required for intellectual property freedom-to-operate (FTO) analysis and patent filings. The programmatic goal of R44AG061995 is to de-risk our novel Alzheimer’s therapeutic development candidate to make this program an attractive investment opportunity for third-party investors and pharmaceutical partners. To arrive at a highly promising patentable development candidate, our workflow involved rigorous lead optimization and candidate selection studies. Vivreon medicinal chemists designed and synthesized new chemical entities (NCEs) with calculated parameters suitable for a CNS drug, which were then tested in potency, ADME, and DMPK assays. These efforts have yielded a candidate therapeutic that demonstrates drug-like properties appropriate for further development. The Vivreon candidate therapeutic is orally bioavailable, highly brain penetrant, and effective in mouse and human models of AD. TABA supplemental funding is urgently required for technical and business services to support intellectual property protections.